approval
saveLEQVIO (INCLISIRAN SODIUM) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 7
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 12, 2026 · 240d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 12, 2026 · 240d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJul 31, 2025 · 436d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJul 7, 2023 · 1191d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 17, 2023 · 1331d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalJun 6, 2022 · 1587d ago
- approvalLEQVIO (INCLISIRAN SODIUM) — FDA approvalDec 22, 2021 · 1753d ago
same company · ±60 days · 6
- approvalasciminib hydrochloride: SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalJun 18, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalJul 11, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalJul 11, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalJul 11, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalJul 11, 2024
- approvalKESIMPTA: KESIMPTA (OFATUMUMAB) — FDA approvalApr 12, 2024
comments(0)
5-min edit window · permanent after that